# COMBAT-CRPC (NCT03554317)

> COMbination of Bipolar Androgen Therapy and Nivolumab

No report yet. It can be ordered.

- Drugs tested: testosterone plus nivolumab
- Indication: metastatic castration-resistant prostate cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03554317
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Conditions: Castration-resistant Prostate Cancer; Metastatic Prostate Cancer; Prostate Cancer
- Interventions: Testosterone cypionate; Nivolumab
- Enrollment: 45
- Primary outcome: Prostate Specific Antigen (PSA) Response to Bipolar Androgen Therapy + Nivolumab

## Indexed commentary on COMBAT-CRPC so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=combat-crpc-nct03554317